Memantine Hydrochloride Tablet
Product Images NDC 71335-2013

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-2013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure diagram of Memantine Hydrochloride, showing its molecular framework with amine and hydrochloride groups labeled.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph showing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment. Two groups are compared: Placebo and Memantine Hydrochloride (M.HCl). The y-axis indicates clinical improvement or decline, with Placebo showing a greater decline over time compared to M.HCl, which shows less decline, suggesting better outcomes with treatment.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A line graph comparing cumulative percentage of patients on the y-axis against ADCS-ADL change from baseline on the x-axis. It shows two curves representing Placebo and Memantine Hydrochloride (M.HCl), indicating differences in patient response over a range of ADCS-ADL scores.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph showing mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine Hydrochloride (M.HCl) and placebo. The x-axis represents weeks of treatment (0 to 28) and the y-axis represents mean change with SEM, ranging from clinical decline to clinical improvement. Two lines illustrate the treatment effect over time for each group.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A cumulative percentage of patients chart comparing Memantine Hydrochloride (M. HCl) and placebo groups based on SIB change from baseline. The x-axis shows SIB change values from approximately +15 to -30, and the y-axis shows cumulative percentage of patients from 0 to 100%. Two lines represent groups: Memantine Hydrochloride (circles) shows a higher cumulative percentage with greater SIB change than the placebo (squares).*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph showing the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. It compares two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The y-axis represents the mean change with SEM, and the x-axis shows weeks of treatment. The graph indicates clinical improvement and decline thresholds.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A line graph depicting the cumulative percentage of patients on the vertical axis versus ADCS-ADL change from baseline on the horizontal axis. Two treatment groups are compared: Placebo/Donepezil (square markers) and Memantine Hydrochloride/Donepezil (circle markers), showing differences in functional change over time.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph depicting the mean change from baseline in SIB score over 24 weeks of treatment. The x-axis shows weeks of treatment (0 to 24), and the y-axis shows the mean ± SEM change from baseline, with a reference line at zero indicating no change. Two groups are shown: Placebo/Donepezil with square markers and M.HCl/Donepezil with circular markers. The M.HCl/Donepezil group shows an initial increase reaching clinical improvement, peaking around week 12, then declines but remains above baseline. The Placebo/Donepezil group remains near baseline and declines after week 18, indicating clinical decline.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A cumulative percentage of patients plot comparing the effect of Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis represents SIB change from baseline, ranging from 20 to -30, while the y-axis shows the cumulative percentage of patients from 0% to 100%. Two curves are shown: one with circles for Memantine Hydrochloride/Donepezil and another with squares for Placebo/Donepezil.*

FDA Label Image

Label (Lbl713352013)

Label for Memantine HCl 5 mg tablet, a human prescription oral tablet packaged by Bryant Ranch Prepack, Burbank, CA. The label includes storage instructions at 20°-25°C (68°-77°F), a warning to keep drugs out of reach of children, a lot number, an NDC of 71335-2013-1, and references Namenda IR 5 mg tablet by Cadila Healthcare Ltd. with a quantity of 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.